Heat Biologics

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Ticker:
HTBX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
HS-110
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
HS-110
Speaker
photo
Chief Executive Officer
Heat Biologics, Inc